Synonyms: erbB-2, CD340
Sarilumab (anti-IL-6Rα) is a fully human anti-IL-6Rα mAb that binds membrane-bound and soluble human IL-6Rα with high affinity, MW: 144.13 KD.
Shimon Sakaguchi
Nature Communications 2025,16, Article number:1325
David Baker
Dev Cell 2023, 58(20):2163-2180.e9.
David Julius
Cell 2017, 185-198.e16
Michael Houghton
Cell Chem Biol, 2020, 27(7):780-792.e5
Charles M. Rice
Cell 2018, 172(3):423-438.e25
| Featured Inhibitors | Y-27632 Dihydrochloride SB431542 CHIR-99021 (Laduviglusib) RMC-7977 RMC-6236 (Daraxonrasib) MRTX1133 MG132 Z-VAD-FMK VT3989 IAG933 |
|---|
| Description |
Sarilumab (anti-IL-6Rα) is a fully human anti-IL-6Rα mAb that binds membrane-bound and soluble human IL-6Rα with high affinity, MW: 144.13 KD.
|
|---|---|
| Features |
Human IgG1
|
| Targets/IC50/Ki |
IL-6R (human)
61.9 pM(Kd)
IL-6R (monkey)
71.9 pM(Kd)
|
| In vitro |
Sarilumab can reverse IL-6 enhanced colony formation in HCC cells under sorafenib or regorafenib treatment. |
| Cell Research |
Cells were treated with drugs for 36 h. The soluble form of IL-6Rα in cell culture supernatants was measured with a human IL-6Rα ELISA kit according to the manufacturer’s instructions. Plates were measured on a microplate reader at a wavelength of 450 nm. |
| In vivo |
Sarilumab has been shown in preclinical studies to inhibit IL-6 signalling in a dose-dependent manner. |
References |
|
| CAS No. | 1189541-98-7 |
|---|---|
| Isotype | Human IgG1 |
| Source | CHO cells |
| Sterility | 0.2 μM filtered |
| Formulation | PBS buffer, pH 7.2 |
| Storage (From the date of receipt) |
Store the undiluted solution at 4°C in the dark to avoid freeze-thaw cycles |
*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|---|
| NCT01042379 | RECRUITING | Drug: Standard Therapy|Drug: AMG 386 with or without Trastuz | Breast Neoplasms; Breast Cancer; Breast Tumors; Angiosarcoma; TNBC - Triple-Negative Breast Cancer; HER2-positive Breast Cancer; HER2-negative Breast Cancer; Hormone Receptor Positive Tumor; Hormone Receptor Negative Tumor; Early-stage Breast Cancer; Locally Advanced Breast Cancer | QuantumLeap Healthcare Collaborative | 2010-03-01 | PHASE2 |
| NCT07154290 | RECRUITING | Drug: Ubamatamab|Drug: Marlotamig|Drug: Sarilumab | Non Small Cell Lung Cancer; Advanced Non Small Cell Lung Cancer; Metastatic Non Small Cell Lung Cancer; Carcinoma Non Small Cell Lung | Regeneron Pharmaceuticals | 2026-03-18 | PHASE2 |
| NCT07286214 | RECRUITING | Drug: Sarilumab|Drug: Sarilumab|Drug: Placebo | Polymyalgia Rheumatica | Sanofi | 2026-05-12 | PHASE4 |
| NCT07704580 | RECRUITING | Drug: Sarilumab, SAR153191 SC|Drug: Sarilumab, SAR153191 IV | Rheumatoid Arthritis | Sanofi | 2026-07-02 | PHASE1; PHASE2 |
| NCT06787612 | RECRUITING | Drug: Ubamatamab|Drug: Bevacizumab|Drug: Cemiplimab|Drug: Fi | Ovarian Cancer; Fallopian Tube Cancer; Primary Peritoneal Cancer | Regeneron Pharmaceuticals | 2025-05-28 | PHASE2 |
| NCT07484113 | NOT_YET_RECRUITING | Drug: Belumosudil|Drug: Sarilumab | cGVHD | Stanford University | 2026-09 | PHASE1 |
(data from https://clinicaltrials.gov, updated on 2026-05-06)
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.
Question 1:
How to store the antibody?
Answer:
Store the undiluted solution at 4 °C in the dark. Freezing antibodies can result in a loss of activity caused by the freezing/thawing process. Diluting antibodies to working concentrations and storing at 4°C for more than a day should be avoided. Additionally, make sure to keep the antibody sterile. Under these storage conditions, your antibodies should remain active for up to one year and oftentimes longer.